P3190 - Mirikizumab Provides Sustained Long-Term Efficacy Up to 4 Years of Treatment for Ulcerative Colitis: Extended Induction Results From the LUCENT-3 Open-Label Study
Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA New York, NY
Award: ACG Presidential Poster Award
Bruce E. Sands, MD, MS, FACG1, David Clemow, PhD2, Geert R. D’Haens, MD, PhD3, Severine Vermeire, MD, PhD4, Peter Irving, MA, MD05, Taku Kobayashi, 6, Laurent Peyrin-Biroulet, MD, PhD7, Karen Samaan, 8, Anil Gaur, 8, Sarah Folian, 8, Ravneet Arora, 8, Nicholas Paquette, PhD9, Richard E.. Moses, DO, JD8, Axel Dignass, MD, PhD10 1Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York, NY; 2Eli Lilly and Company, Indianapolis, IL; 3Department of Gastroenterology, Amsterdam University Medical Center, Amsterdam, Noord-Holland, Netherlands; 4Department of Gastroenterology & Hepatology, University hospital Leuven, Leuven, Brabant Wallon, Belgium; 5Guy's and St. Thomas’ Hospitals, London, England, United Kingdom; 6Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Tokyo, Japan; 7Department of Gastroenterology, CHRU Nancy, INSERM NGERE, Université de Lorraine, France, Vandœuvre-lès-Nancy, Lorraine, France; 8Eli Lilly and Company, Indianapolis, IN; 9Syneos Health, Morrisville, NC; 10Agaplesion Markus Hospital, Frankfurt, Hessen, Germany Introduction: Mirikizumab, a p19-directed interleukin-23 monoclonal antibody, is efficacious inducing clinical remission at Week(W) 12 and maintaining clinical remission through W212 in patients with moderately-to-severely active ulcerative colitis (LUCENT-1: W0-W12, NCT03518086; LUCENT-2: W12-W52, NCT03524092; LUCENT-3: W52-W212, NCT03519945). Here we present efficacy and safety through W212 of mirikizumab extended induction from the open-label LUCENT-3 study. Methods: Symptomatic, clinical, endoscopic, histologic, corticosteroid-free (CSF), bowel urgency, quality-of-life, and adverse event (AE) outcomes are reported for mirikizumab extended induction (intravenous every 4W for 24W) responders, including patients with biologic failure, who entered LUCENT-3, with data from W52 maintenance remitters. Discontinuations or missing data were handled by nonresponder imputation (NRI), modified NRI (mNRI), and observed case (OC). mNRI uses multiple imputation for missing data and balances biases of NRI and OC. Table 1 provides endpoint and population definitions for extended induction remitters. Efficacy population N=52. Safety population N=150. Results: Using mNRI, mirikizumab extended induction W52 clinical remitters demonstrated 74% clinical response at W212. Remission rates at W212 among W52 clinical remitters were: symptomatic remission, 71%; clinical remission, 54%; endoscopic remission, 60%; histologic-endoscopic mucosal remission, 43%; CSF remission, 49%; bowel urgency remission, 62%; and Inflammatory Bowel Disease Questionnaire remission, 76%. Bowel urgency clinically meaningful improvement at W212 was achieved in 70% of patients. Biologic Failed/Not Biologic Failed subgroup data also demonstrated maintenance of efficacy (Table 1). Stool frequency, rectal bleeding, and bowel urgency score reductions from induction baseline at W52 for maintenance completers with mixed model repeated measures were sustained through W212. For W0-W160 of LUCENT-3, serious AEs were reported in 14% of patients, while 9% discontinued treatment due to an AE. Discussion: For UC patients refractory to initial induction treatment, mirikizumab extended induction provides sustained long-term symptomatic, clinical, endoscopic, histologic, corticosteroid-free, and quality-of-life remission up to 4 years in patients with UC, including for biologic failed patients, with no new safety concerns.
Figure: Table 1: Summary of mirikizumab efficacy at Week 212 in Week 52 remitters.
Bruce E. Sands, MD, MS, FACG1, David Clemow, PhD2, Geert R. D’Haens, MD, PhD3, Severine Vermeire, MD, PhD4, Peter Irving, MA, MD05, Taku Kobayashi, 6, Laurent Peyrin-Biroulet, MD, PhD7, Karen Samaan, 8, Anil Gaur, 8, Sarah Folian, 8, Ravneet Arora, 8, Nicholas Paquette, PhD9, Richard E.. Moses, DO, JD8, Axel Dignass, MD, PhD10. P3190 - Mirikizumab Provides Sustained Long-Term Efficacy Up to 4 Years of Treatment for Ulcerative Colitis: Extended Induction Results From the LUCENT-3 Open-Label Study, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.